CR20230485A - Derivados de fósforo como nuevos inhibidores de sos1 - Google Patents

Derivados de fósforo como nuevos inhibidores de sos1

Info

Publication number
CR20230485A
CR20230485A CR20230485A CR20230485A CR20230485A CR 20230485 A CR20230485 A CR 20230485A CR 20230485 A CR20230485 A CR 20230485A CR 20230485 A CR20230485 A CR 20230485A CR 20230485 A CR20230485 A CR 20230485A
Authority
CR
Costa Rica
Prior art keywords
compounds
novel
phosphorus derivatives
sos1
preparation
Prior art date
Application number
CR20230485A
Other languages
English (en)
Inventor
Timo Stellfeld
Keith Graham
Jens SCHRÖDER
Michael Erkelenz
Steffen Gressies
Atanas Marinov Kamburov
Roman Hillig
Christoph Philipp Hethey
Jeremie Xavier G Mortier
Matthias Arlt
Benjamin Bader
Katrin Nowak-Reppel
Felix Pape
Gerhard Siemeister
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of CR20230485A publication Critical patent/CR20230485A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
    • C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6568—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus atoms as the only ring hetero atoms
    • C07F9/65685—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus atoms as the only ring hetero atoms the ring phosphorus atom being part of a phosphine oxide or thioxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención abarca los derivados de fósforo de la fórmula general (I): (I), en donde R<em>1</em>, R<em>2</em>, R<em>3</em>, R<em>4</em>, R<em>5</em>, R<em>6</em>, X<em>1</em>, X<em>2</em>, X<em>3</em>, X<em>4</em> e Y son como se definen en el presente documento, métodos de preparación de dichos compuestos, compuestos intermedios útiles para la preparación de dichos compuestos, composiciones farmacéuticas y combinaciones que comprenden dichos compuestos y el uso de dichos compuestos para la fabricación de composiciones farmacéuticas para el tratamiento o profilaxis de enfermedades, en particular de trastornos hiperproliferativos, especialmente enfermedades asociadas a SOS1, como agente único o en combinación con otros ingredientes activos.
CR20230485A 2021-04-14 2022-04-13 Derivados de fósforo como nuevos inhibidores de sos1 CR20230485A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21168256.2A EP4074317A1 (en) 2021-04-14 2021-04-14 Phosphorus derivatives as novel sos1 inhibitors
PCT/EP2022/059857 WO2022219035A1 (en) 2021-04-14 2022-04-13 Phosphorus derivatives as novel sos1 inhibitors

Publications (1)

Publication Number Publication Date
CR20230485A true CR20230485A (es) 2023-12-12

Family

ID=75529812

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20230485A CR20230485A (es) 2021-04-14 2022-04-13 Derivados de fósforo como nuevos inhibidores de sos1

Country Status (22)

Country Link
US (1) US20240247015A1 (es)
EP (2) EP4074317A1 (es)
JP (1) JP2024513595A (es)
KR (1) KR20230170032A (es)
CN (1) CN117500507A (es)
AR (1) AR125672A1 (es)
AU (1) AU2022258751A1 (es)
BR (1) BR112023019030A2 (es)
CA (1) CA3216503A1 (es)
CL (1) CL2023003045A1 (es)
CO (1) CO2023013469A2 (es)
CR (1) CR20230485A (es)
DO (1) DOP2023000218A (es)
EC (1) ECSP23077322A (es)
GE (1) GEAP202316387A (es)
IL (1) IL307448A (es)
JO (1) JOP20230252A1 (es)
MX (1) MX2023012187A (es)
PE (1) PE20240022A1 (es)
PH (1) PH12023552869A1 (es)
TW (1) TW202304467A (es)
WO (1) WO2022219035A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021228028A1 (zh) * 2020-05-09 2021-11-18 正大天晴药业集团股份有限公司 含磷的sos1抑制剂
EP4214204A1 (en) * 2020-09-18 2023-07-26 Bayer Aktiengesellschaft Pyrido[2,3-d]pyrimidin-4-amines as sos1 inhibitors
CN116425796A (zh) * 2022-01-12 2023-07-14 如东凌达生物医药科技有限公司 一类嘧啶并杂环类化合物、制备方法和用途
CN119894893A (zh) * 2022-09-16 2025-04-25 拜耳公司 用于治疗癌症的砜取代的吡啶并[3,4-d]嘧啶衍生物
WO2024211663A1 (en) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Condensed macrocyclic compounds as ras inhibitors
EP4688790A1 (en) 2023-04-07 2026-02-11 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2024216016A1 (en) 2023-04-14 2024-10-17 Revolution Medicines, Inc. Crystalline forms of a ras inhibitor
AU2024252105A1 (en) 2023-04-14 2025-10-16 Revolution Medicines, Inc. Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
WO2026032865A1 (en) 2024-08-09 2026-02-12 Bayer Aktiengesellschaft Salt of a sos-1 inhibitor

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2015A (en) 1841-03-26 Improvement in rotary steam-engines
IL89027A (en) 1988-01-29 1993-01-31 Lilly Co Eli Quinazoline derivatives, process for their preparation and fungicidal, insecticidal and miticidal compositions containing them
GT198900008A (es) 1988-01-29 1990-07-17 Derivados de quinolina, quinazolina y cinolina.
PT100905A (pt) 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
US5236925A (en) 1991-10-24 1993-08-17 American Home Products Corporation Fused pyrimidines as angiotensin II antagonists
ES2277389T3 (es) 1997-08-25 2007-07-01 Bayer Corporation Cetonas heterociclicas como antagonistas npy 15.
GB0112834D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
AU2003299943A1 (en) * 2002-12-23 2004-07-22 Ariad Pharmaceuticals, Inc. Heterocycles and uses thereof
TW200508224A (en) 2003-02-12 2005-03-01 Bristol Myers Squibb Co Cyclic derivatives as modulators of chemokine receptor activity
WO2005005382A2 (en) 2003-07-02 2005-01-20 Cytokinetics, Inc. Compounds, compositions and methods
EP1656379B1 (en) 2003-08-15 2007-01-10 Merck & Co., Inc. 4-cycloalkylaminopyrazolo pyrimidine nmda/nr2b antagonists
CN1976907A (zh) 2004-04-30 2007-06-06 武田药品工业株式会社 杂环酰胺化合物及其作为mmp－13抑制剂的用途
SE0401540D0 (sv) 2004-06-15 2004-06-15 Astrazeneca Ab New compounds
ITMI20042042A1 (it) 2004-10-26 2005-01-26 Pharmeste Srl Derivati solfonammidici antagonisti del recettore dei vanilloidi trpv1
ES2569881T3 (es) 2005-06-08 2016-05-12 The University Of North Carolina At Chapel Hill Procedimientos para facilitar la supervivencia de células neuronales usando miméticos de neurotrofina BDNF peptídicos y no peptídicos
CA2651573C (en) 2006-05-23 2011-12-06 F. Hoffmann-La Roche Ag Pyridopyrimidinone derivatives
EP2137162B1 (en) 2007-03-15 2018-08-01 Novartis AG Organic compounds and their uses
JP2008280341A (ja) 2007-04-12 2008-11-20 Sumitomo Chemical Co Ltd ヒドラジド化合物およびその防除用途
US20090099195A1 (en) 2007-05-08 2009-04-16 Astrazeneca Ab Therapeutic Compounds 570
FR2929615B1 (fr) 2008-04-02 2010-12-17 Tfchem Composes c-aryl glycosides pour le traitement du diabete et de l'obesite.
EP2300013B2 (en) 2008-05-21 2024-11-13 Takeda Pharmaceutical Company Limited Phosphorous derivatives as kinase inhibitors
EP2318377B1 (en) 2008-07-31 2013-08-21 Genentech, Inc. Pyrimidine compounds, compositions and methods of use
PE20110300A1 (es) 2008-08-27 2011-06-16 Takeda Pharmaceutical Compuestos de pirrol como inhibidores de la bomba de protones
PL2401267T3 (pl) 2009-02-27 2014-06-30 Ambit Biosciences Corp Pochodne chinazoliny modulujące kinazę JAK i ich zastosowanie w metodach
US8461164B2 (en) 2009-08-31 2013-06-11 Dow Agrosciences, Llc. Pteridines and their use as agrochemicals
ES2900504T3 (es) 2009-09-03 2022-03-17 Bristol Myers Squibb Co Quinazolinas como inhibidores de los canales iónicos de potasio
EP2611502A1 (en) 2010-09-01 2013-07-10 Ambit Biosciences Corporation Adenosine a3 receptor modulating compounds and methods of use thereof
AU2011296024B2 (en) 2010-09-01 2015-05-28 Ambit Biosciences Corporation Quinazoline compounds and methods of use thereof
WO2012030912A1 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation 7-cyclylquinazoline derivatives and methods of use thereof
RU2013114710A (ru) 2010-09-03 2014-10-10 Байер Интеллектуэль Проперти Гмбх Замещенные конденсированные пиримидиноны и дигидропиримидиноны
US8552200B2 (en) 2010-10-20 2013-10-08 Gruenenthal Gmbh Substituted 6-amino-nicotinamides as KCNQ2/3 modulators
WO2012066122A1 (en) 2010-11-18 2012-05-24 Syngenta Participations Ag 2 - (pyridin- 2 -yl) -quinazoline derivatives and their use as microbicides
PY1153144A (es) 2010-12-10 2015-01-01 Gilead Sciences Inc Inhibidores macrocíclicos de virus flaviviridae
CN102584828B (zh) 2011-01-14 2016-01-27 上海艾力斯医药科技有限公司 吡咯烷[3，4-d]嘧啶衍生物、制备方法及其应用
WO2012112363A1 (en) 2011-02-14 2012-08-23 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
US8846656B2 (en) 2011-07-22 2014-09-30 Novartis Ag Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators
CN102911172A (zh) 2011-08-04 2013-02-06 上海恒瑞医药有限公司 杂芳基并嘧啶类衍生物、其制备方法和用途
WO2013030138A1 (en) 2011-09-01 2013-03-07 F. Hoffmann-La Roche Ag Pyrrolopyrazine kinase inhibitors
CN103387490B (zh) 2012-05-09 2015-08-26 中国科学院兰州化学物理研究所 一种甲苯羰化合成苯乙酸的方法
WO2013185103A1 (en) 2012-06-08 2013-12-12 Gilead Sciences, Inc. Macrocyclic inhibitors of flaviviridae viruses
JP6391120B2 (ja) 2012-12-20 2018-09-19 サンフォード−バーンハム メディカル リサーチ インスティテュート ニューロテンシン受容体１の小分子アゴニスト
PE20151722A1 (es) 2013-01-08 2015-11-19 European Molecular Biology Lab Embl Derivados de pirimidona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral
WO2014153667A1 (en) 2013-03-29 2014-10-02 Vida Therapeutics, Inc. Cosmetic uses and methods for indoline granzyme b inhibitor compositions
TWI527811B (zh) 2013-05-09 2016-04-01 吉李德科學股份有限公司 作爲溴結構域抑制劑的苯並咪唑衍生物
JP6159028B2 (ja) 2013-07-31 2017-07-05 ギリアード サイエンシーズ， インコーポレイテッド Ｓｙｋ阻害剤
WO2015155306A1 (en) 2014-04-11 2015-10-15 Almirall, S.A. New trpa1 antagonists
CA2957898C (en) 2014-09-15 2023-02-21 Rugen Holdings (Cayman) Limited Pyrrolopyrimidine derivatives as nr2b nmda receptor antagonists
EP3453710B1 (en) 2014-09-17 2022-09-21 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
WO2016049048A1 (en) 2014-09-22 2016-03-31 Rugen Holdings (Cayman) Limited Treatment of anxiety disorders and autism spectrum disorders
CN104803954B (zh) 2015-04-30 2018-01-26 上海应用技术学院 一种福沙那韦中间体的制备方法
SI3319939T1 (sl) 2015-07-08 2025-04-30 Cv6 Therapeutics (Ni) Limited Zaviralci deoksiuridin trifosfataze, ki vsebujejo hidantoin
WO2017069275A1 (ja) 2015-10-22 2017-04-27 田辺三菱製薬株式会社 新規二環性複素環化合物
GB201616839D0 (en) 2016-10-04 2016-11-16 Takeda Pharmaceutical Company Limited Therapeutic compounds
WO2018112842A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. 6,6-fused heteroaryl piperidine ether allosteric modulators of m4 muscarinic acetylcholine receptor
US10898487B2 (en) * 2016-12-22 2021-01-26 Boehringer Ingelheim International Gmbh Benzylamino substituted quinazolines and derivatives as SOS1 inhibitors
GB201700814D0 (en) 2017-01-17 2017-03-01 Liverpool School Tropical Medicine Compounds
US20220235013A1 (en) 2017-03-21 2022-07-28 Bayer Pharma Aktiengesellschaft 2-methyl-quinazolines
FR3066761B1 (fr) 2017-05-23 2020-10-30 Centre Nat Rech Scient Nouveaux composes inhibiteurs des canaux ioniques
ES2944306T3 (es) 2017-12-21 2023-06-20 Boehringer Ingelheim Int Piridopirimidinonas sustituidas por bencilamino y derivados como inhibidores de SOS1
SG11202008504SA (en) 2018-03-05 2020-10-29 Bristol Myers Squibb Co Phenylpyrrolidinone formyl peptide 2 receptor agonists
CN109776607B (zh) 2019-02-21 2021-06-04 青岛海洋生物医药研究院 芳基磷氧类和芳基磷硫类化合物及其制备方法和应用
EP3930845A1 (en) 2019-03-01 2022-01-05 Revolution Medicines, Inc. Bicyclic heterocyclyl compounds and uses thereof
JP2022522777A (ja) 2019-03-01 2022-04-20 レボリューション メディシンズ インコーポレイテッド 二環式ヘテロアリール化合物及びその使用
WO2021228028A1 (zh) * 2020-05-09 2021-11-18 正大天晴药业集团股份有限公司 含磷的sos1抑制剂

Also Published As

Publication number Publication date
CO2023013469A2 (es) 2024-04-29
KR20230170032A (ko) 2023-12-18
GEAP202316387A (en) 2023-12-25
EP4322962A1 (en) 2024-02-21
EP4074317A1 (en) 2022-10-19
CN117500507A (zh) 2024-02-02
AR125672A1 (es) 2023-08-02
WO2022219035A1 (en) 2022-10-20
BR112023019030A2 (pt) 2023-10-24
AU2022258751A1 (en) 2023-10-05
JOP20230252A1 (ar) 2023-10-12
PE20240022A1 (es) 2024-01-04
MX2023012187A (es) 2023-10-25
US20240247015A1 (en) 2024-07-25
DOP2023000218A (es) 2023-11-15
JP2024513595A (ja) 2024-03-26
CL2023003045A1 (es) 2024-03-22
TW202304467A (zh) 2023-02-01
IL307448A (en) 2023-12-01
ECSP23077322A (es) 2023-11-30
PH12023552869A1 (en) 2024-05-20
CA3216503A1 (en) 2022-10-20

Similar Documents

Publication Publication Date Title
CL2023003045A1 (es) Derivados de fósforo como nuevos inhibidores de sos1
CL2021001042A1 (es) Nuevos compuestos antihelmínticos
CO2018010966A2 (es) Nuevos derivados de pirazolopirimidina
DOP2019000206A (es) 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas
MX2019005009A (es) 1,2,4-triazolonas 2,4,5-trisustituidas.
JOP20220131A1 (ar) مركبات أمينو كينولون تحمل بدائل تستخدم كمثبطات لـ dgkalpha من أجل تنشيط المناعة
CL2022002919A1 (es) Aminotiazoles sustituidos como inhibidores de dgkzeta para la activación inmune
MX2022006700A (es) Compuestos poliheterociclicos como inhibidores de mettl3.
ECSP20008441A (es) Dihidrooxadiazinonas
CO2020001244A2 (es) Derivados de quinolina para tratar infecciones con helmintos
ECSP034916A (es) Oxazolidinonas substituidas para terapia de combinacion
CO2020013876A2 (es) Nuevos derivados de quinolina
CO2019011877A2 (es) Nuevos derivados de pirazol bicíclicos
MX2022001803A (es) [1,2,4]triazolo[1,5-c]quinazolin-5-aminas.
UY38816A (es) Nuevos derivados de isoquinolina
CL2023003921A1 (es) Inhibidores de transglutaminasas
CL2024000710A1 (es) Nuevos derivados de quinolina
PA8627001A1 (es) Compuestos para el tratamiento de enfermedades
MX2023015490A (es) Inhibidores de las transglutaminasas.
CO2024000832A2 (es) Inhibidores de transglutaminasas
GT200500214A (es) Amidas del acido 5 y 6-aminoalquil indol-2-carboxilico 3-sustituidas y análogos relacionados como inhibidores de la caseína cinasa epsilon
CL2025002072A1 (es) Inhibidores de prmt5–mta.